JP2018531937A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018531937A5 JP2018531937A5 JP2018517270A JP2018517270A JP2018531937A5 JP 2018531937 A5 JP2018531937 A5 JP 2018531937A5 JP 2018517270 A JP2018517270 A JP 2018517270A JP 2018517270 A JP2018517270 A JP 2018517270A JP 2018531937 A5 JP2018531937 A5 JP 2018531937A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- subject
- mutation
- treatment
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 194
- 230000035772 mutation Effects 0.000 claims 112
- 108700028369 Alleles Proteins 0.000 claims 86
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 57
- 208000035475 disorder Diseases 0.000 claims 57
- 230000004777 loss-of-function mutation Effects 0.000 claims 42
- 108010069820 Pro-Opiomelanocortin Proteins 0.000 claims 35
- 108090000623 proteins and genes Proteins 0.000 claims 33
- 229920012196 Polyoxymethylene Copolymer Polymers 0.000 claims 32
- 102100027467 Pro-opiomelanocortin Human genes 0.000 claims 32
- 108010092277 Leptin Proteins 0.000 claims 30
- 102000016267 Leptin Human genes 0.000 claims 26
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims 26
- 229940039781 leptin Drugs 0.000 claims 26
- 125000002252 acyl group Chemical group 0.000 claims 24
- 230000037406 food intake Effects 0.000 claims 24
- 102100032378 Carboxypeptidase E Human genes 0.000 claims 22
- 108010058255 Carboxypeptidase H Proteins 0.000 claims 22
- 235000012631 food intake Nutrition 0.000 claims 21
- 239000000556 agonist Substances 0.000 claims 20
- 101710149236 Helix-loop-helix protein 2 Proteins 0.000 claims 19
- 102100021889 Helix-loop-helix protein 2 Human genes 0.000 claims 19
- 102000001796 Melanocortin 4 receptors Human genes 0.000 claims 19
- 108010021436 Type 4 Melanocortin Receptor Proteins 0.000 claims 19
- 125000000304 alkynyl group Chemical group 0.000 claims 18
- 230000037430 deletion Effects 0.000 claims 17
- 238000012217 deletion Methods 0.000 claims 17
- 108010072553 5-HT2C Serotonin Receptor Proteins 0.000 claims 16
- 108010019813 leptin receptors Proteins 0.000 claims 16
- 125000000217 alkyl group Chemical group 0.000 claims 15
- 230000036772 blood pressure Effects 0.000 claims 15
- -1 D-1-Nal Chemical compound 0.000 claims 14
- 101150093308 POMC gene Proteins 0.000 claims 13
- 239000000969 carrier Substances 0.000 claims 13
- 108010044159 Proprotein Convertases Proteins 0.000 claims 12
- 125000003342 alkenyl group Chemical group 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 12
- 125000004404 heteroalkyl group Chemical group 0.000 claims 12
- 235000003642 hunger Nutrition 0.000 claims 12
- 125000003107 substituted aryl group Chemical group 0.000 claims 12
- 101000578943 Homo sapiens MAGE-like protein 2 Proteins 0.000 claims 11
- 102100028333 MAGE-like protein 2 Human genes 0.000 claims 11
- 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 claims 10
- 101100512259 Homo sapiens MAGEL2 gene Proteins 0.000 claims 10
- 101001128694 Homo sapiens Neuroendocrine convertase 1 Proteins 0.000 claims 10
- 101150042280 MAGEL2 gene Proteins 0.000 claims 10
- 102100032132 Neuroendocrine convertase 1 Human genes 0.000 claims 10
- 230000037396 body weight Effects 0.000 claims 10
- 102000005861 leptin receptors Human genes 0.000 claims 10
- 102000006437 Proprotein Convertases Human genes 0.000 claims 9
- 235000021316 daily nutritional intake Nutrition 0.000 claims 9
- 230000035487 diastolic blood pressure Effects 0.000 claims 9
- 201000001321 Bardet-Biedl syndrome Diseases 0.000 claims 7
- 201000010769 Prader-Willi syndrome Diseases 0.000 claims 7
- 230000037361 pathway Effects 0.000 claims 7
- 238000010254 subcutaneous injection Methods 0.000 claims 7
- 239000007929 subcutaneous injection Substances 0.000 claims 7
- 125000000923 (C1-C30) alkyl group Chemical group 0.000 claims 6
- JPZXHKDZASGCLU-GFCCVEGCSA-N 3-(2-Naphthyl)-D-Alanine Chemical compound C1=CC=CC2=CC(C[C@@H](N)C(O)=O)=CC=C21 JPZXHKDZASGCLU-GFCCVEGCSA-N 0.000 claims 6
- 208000021351 Bardet-Biedl syndrome 20 Diseases 0.000 claims 6
- 125000000739 C2-C30 alkenyl group Chemical group 0.000 claims 6
- 108091029523 CpG island Proteins 0.000 claims 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N Cysteine Chemical compound SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 6
- XUJNEKJLAYXESH-UWTATZPHSA-N D-Cysteine Chemical compound SC[C@@H](N)C(O)=O XUJNEKJLAYXESH-UWTATZPHSA-N 0.000 claims 6
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims 6
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 6
- 150000008575 L-amino acids Chemical class 0.000 claims 6
- 101150071716 PCSK1 gene Proteins 0.000 claims 6
- 238000001802 infusion Methods 0.000 claims 6
- 238000002347 injection Methods 0.000 claims 6
- 239000007924 injection Substances 0.000 claims 6
- 230000000284 resting effect Effects 0.000 claims 6
- 208000011580 syndromic disease Diseases 0.000 claims 6
- 230000035488 systolic blood pressure Effects 0.000 claims 6
- 238000002560 therapeutic procedure Methods 0.000 claims 6
- HWPZZUQOWRWFDB-UHFFFAOYSA-N 1-methylcytosine Chemical compound CN1C=CC(N)=NC1=O HWPZZUQOWRWFDB-UHFFFAOYSA-N 0.000 claims 5
- 102100030461 Alpha-ketoglutarate-dependent dioxygenase FTO Human genes 0.000 claims 5
- 102100032360 Alstrom syndrome protein 1 Human genes 0.000 claims 5
- 102100035080 BDNF/NT-3 growth factors receptor Human genes 0.000 claims 5
- 102100022802 BTB/POZ domain-containing protein KCTD15 Human genes 0.000 claims 5
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims 5
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims 5
- 150000008574 D-amino acids Chemical class 0.000 claims 5
- 102100036702 Glucosamine-6-phosphate isomerase 2 Human genes 0.000 claims 5
- 101001062620 Homo sapiens Alpha-ketoglutarate-dependent dioxygenase FTO Proteins 0.000 claims 5
- 101000797795 Homo sapiens Alstrom syndrome protein 1 Proteins 0.000 claims 5
- 101000596896 Homo sapiens BDNF/NT-3 growth factors receptor Proteins 0.000 claims 5
- 101000974798 Homo sapiens BTB/POZ domain-containing protein KCTD15 Proteins 0.000 claims 5
- 101000710899 Homo sapiens Cannabinoid receptor 1 Proteins 0.000 claims 5
- 101001072480 Homo sapiens Glucosamine-6-phosphate isomerase 2 Proteins 0.000 claims 5
- 101000599629 Homo sapiens Insulin-induced gene 2 protein Proteins 0.000 claims 5
- 101001013832 Homo sapiens Mitochondrial peptide methionine sulfoxide reductase Proteins 0.000 claims 5
- 101001124388 Homo sapiens NPC intracellular cholesterol transporter 1 Proteins 0.000 claims 5
- 101000812677 Homo sapiens Nucleotide pyrophosphatase Proteins 0.000 claims 5
- 101001084276 Homo sapiens Phosphotriesterase-related protein Proteins 0.000 claims 5
- 101000663006 Homo sapiens Poly [ADP-ribose] polymerase tankyrase-1 Proteins 0.000 claims 5
- 101001116937 Homo sapiens Protocadherin alpha-4 Proteins 0.000 claims 5
- 101000740529 Homo sapiens Serologically defined colon cancer antigen 8 Proteins 0.000 claims 5
- 101000597758 Homo sapiens Transmembrane protein 18 Proteins 0.000 claims 5
- 101000667110 Homo sapiens Vacuolar protein sorting-associated protein 13B Proteins 0.000 claims 5
- 102100037970 Insulin-induced gene 2 protein Human genes 0.000 claims 5
- 101800002739 Melanin-concentrating hormone Proteins 0.000 claims 5
- 102100027375 Melanin-concentrating hormone receptor 1 Human genes 0.000 claims 5
- 108700036626 Melanin-concentrating hormone receptor 1 Proteins 0.000 claims 5
- 102100031767 Mitochondrial peptide methionine sulfoxide reductase Human genes 0.000 claims 5
- 102100029565 NPC intracellular cholesterol transporter 1 Human genes 0.000 claims 5
- 102100039306 Nucleotide pyrophosphatase Human genes 0.000 claims 5
- 102100030961 Phosphotriesterase-related protein Human genes 0.000 claims 5
- 102100037664 Poly [ADP-ribose] polymerase tankyrase-1 Human genes 0.000 claims 5
- 102100033721 Pro-MCH Human genes 0.000 claims 5
- 102100024261 Protocadherin alpha-4 Human genes 0.000 claims 5
- 101150052097 SH2B1 gene Proteins 0.000 claims 5
- 102100037221 Serologically defined colon cancer antigen 8 Human genes 0.000 claims 5
- 102100039189 Transcription factor Maf Human genes 0.000 claims 5
- 102100035318 Transmembrane protein 18 Human genes 0.000 claims 5
- 102100039113 Vacuolar protein sorting-associated protein 13B Human genes 0.000 claims 5
- 230000007812 deficiency Effects 0.000 claims 5
- 230000002950 deficient Effects 0.000 claims 5
- 101000960114 Homo sapiens Intraflagellar transport protein 172 homolog Proteins 0.000 claims 4
- 102100039929 Intraflagellar transport protein 172 homolog Human genes 0.000 claims 4
- 210000000349 chromosome Anatomy 0.000 claims 4
- 238000001514 detection method Methods 0.000 claims 4
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N Arginine Chemical compound OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 3
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims 3
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims 3
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- 208000008589 Obesity Diseases 0.000 claims 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 3
- 238000013542 behavioral therapy Methods 0.000 claims 3
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 3
- 230000037213 diet Effects 0.000 claims 3
- 235000005911 diet Nutrition 0.000 claims 3
- 238000009207 exercise therapy Methods 0.000 claims 3
- 230000000977 initiatory effect Effects 0.000 claims 3
- 208000001022 morbid obesity Diseases 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- 230000003204 osmotic effect Effects 0.000 claims 3
- 229940071643 prefilled syringe Drugs 0.000 claims 3
- 238000002203 pretreatment Methods 0.000 claims 3
- 102000005962 receptors Human genes 0.000 claims 3
- 108020003175 receptors Proteins 0.000 claims 3
- 230000004580 weight loss Effects 0.000 claims 3
- 101150005161 ALMS1 gene Proteins 0.000 claims 2
- 101100162491 Homo sapiens ALMS1 gene Proteins 0.000 claims 2
- 101150040471 19 gene Proteins 0.000 claims 1
- 101150098072 20 gene Proteins 0.000 claims 1
- 206010068783 Alstroem syndrome Diseases 0.000 claims 1
- 201000005932 Alstrom Syndrome Diseases 0.000 claims 1
- 206010064571 Gene mutation Diseases 0.000 claims 1
- 206010056715 Laurence-Moon-Bardet-Biedl syndrome Diseases 0.000 claims 1
- 108010008364 Melanocortins Proteins 0.000 claims 1
- 101100001471 Schizosaccharomyces pombe (strain 972 / ATCC 24843) alm1 gene Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 230000006607 hypermethylation Effects 0.000 claims 1
- 230000008774 maternal effect Effects 0.000 claims 1
- 239000002865 melanocortin Substances 0.000 claims 1
- 230000011987 methylation Effects 0.000 claims 1
- 238000007069 methylation reaction Methods 0.000 claims 1
- 230000008775 paternal effect Effects 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021064764A JP7752373B2 (ja) | 2015-09-30 | 2021-04-06 | メラノコルチン４受容体経路関連障害を治療する方法 |
| JP2022155051A JP2022173426A (ja) | 2015-09-30 | 2022-09-28 | メラノコルチン４受容体経路関連障害を治療する方法 |
| JP2024204921A JP2025019234A (ja) | 2015-09-30 | 2024-11-25 | メラノコルチン４受容体経路関連障害を治療する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562235003P | 2015-09-30 | 2015-09-30 | |
| US62/235,003 | 2015-09-30 | ||
| PCT/US2016/054457 WO2017059076A1 (en) | 2015-09-30 | 2016-09-29 | Method of treating melanocortin-4 receptor pathway-associated disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021064764A Division JP7752373B2 (ja) | 2015-09-30 | 2021-04-06 | メラノコルチン４受容体経路関連障害を治療する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018531937A JP2018531937A (ja) | 2018-11-01 |
| JP2018531937A5 true JP2018531937A5 (enExample) | 2019-11-07 |
| JP6940853B2 JP6940853B2 (ja) | 2021-09-29 |
Family
ID=57138146
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018517270A Active JP6940853B2 (ja) | 2015-09-30 | 2016-09-29 | メラノコルチン４受容体経路関連障害を治療する方法 |
| JP2018517274A Active JP7051106B2 (ja) | 2015-09-30 | 2016-09-29 | メラノコルチン－４受容体経路関連障害の治療方法 |
| JP2021041611A Pending JP2021088611A (ja) | 2015-09-30 | 2021-03-15 | メラノコルチン−４受容体経路関連障害の治療方法 |
| JP2021064764A Active JP7752373B2 (ja) | 2015-09-30 | 2021-04-06 | メラノコルチン４受容体経路関連障害を治療する方法 |
| JP2022155051A Pending JP2022173426A (ja) | 2015-09-30 | 2022-09-28 | メラノコルチン４受容体経路関連障害を治療する方法 |
| JP2023044399A Pending JP2023078335A (ja) | 2015-09-30 | 2023-03-20 | メラノコルチン－４受容体経路関連障害の治療方法 |
| JP2024204921A Pending JP2025019234A (ja) | 2015-09-30 | 2024-11-25 | メラノコルチン４受容体経路関連障害を治療する方法 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018517274A Active JP7051106B2 (ja) | 2015-09-30 | 2016-09-29 | メラノコルチン－４受容体経路関連障害の治療方法 |
| JP2021041611A Pending JP2021088611A (ja) | 2015-09-30 | 2021-03-15 | メラノコルチン−４受容体経路関連障害の治療方法 |
| JP2021064764A Active JP7752373B2 (ja) | 2015-09-30 | 2021-04-06 | メラノコルチン４受容体経路関連障害を治療する方法 |
| JP2022155051A Pending JP2022173426A (ja) | 2015-09-30 | 2022-09-28 | メラノコルチン４受容体経路関連障害を治療する方法 |
| JP2023044399A Pending JP2023078335A (ja) | 2015-09-30 | 2023-03-20 | メラノコルチン－４受容体経路関連障害の治療方法 |
| JP2024204921A Pending JP2025019234A (ja) | 2015-09-30 | 2024-11-25 | メラノコルチン４受容体経路関連障害を治療する方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (5) | US20180215790A1 (enExample) |
| EP (4) | EP4360704A3 (enExample) |
| JP (7) | JP6940853B2 (enExample) |
| KR (1) | KR20180063221A (enExample) |
| CN (2) | CN108601816A (enExample) |
| AU (6) | AU2016330772A1 (enExample) |
| BR (1) | BR112018006674A2 (enExample) |
| CA (2) | CA3000673A1 (enExample) |
| DK (1) | DK3356386T3 (enExample) |
| ES (1) | ES2985734T3 (enExample) |
| FI (1) | FI3356386T3 (enExample) |
| HK (1) | HK1259424A1 (enExample) |
| IL (3) | IL299541A (enExample) |
| MA (2) | MA43040A (enExample) |
| MX (2) | MX2018003983A (enExample) |
| PL (1) | PL3356386T3 (enExample) |
| PT (1) | PT3356386T (enExample) |
| SG (1) | SG10202101510XA (enExample) |
| WO (2) | WO2017059075A1 (enExample) |
| ZA (1) | ZA201802704B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3539551T (lt) | 2011-12-29 | 2022-01-10 | Rhythm Pharmaceuticals, Inc. | Su melanokortino-4 receptoriumi susijusių sutrikimų gydymo būdas heterozigotiniuose nešiotojuose |
| PT3356386T (pt) | 2015-09-30 | 2024-05-17 | Rhythm Pharmaceuticals Inc | Método de tratamento de distúrbios associados à via do receptor da melanocortina-4 |
| UY37969A (es) * | 2017-11-15 | 2019-06-28 | Rhythm Pharmaceuticals Inc | Formulaciones de peptidos de liberación sostenida |
| US20210052551A1 (en) | 2018-02-20 | 2021-02-25 | Charite - Universitatsmedizin Berlin | MC4R Agonist Efficacy in Subjects with MC4R Deficiencies and Impaired NFAT Signaling |
| US20210221867A1 (en) | 2018-05-15 | 2021-07-22 | Novo Nordisk A/S | Compounds Capable of Binding to Melanocortin 4 Receptor |
| CN108841932B (zh) * | 2018-07-13 | 2021-03-12 | 东北农业大学 | 一种预示和鉴定鸡腹部脂肪量的分子标记方法及应用 |
| AU2021268327A1 (en) * | 2020-05-04 | 2022-12-15 | Regeneron Pharmaceuticals, Inc. | Proprotein convertase subtilisin/kexin type 1 (PCSK1) variants and uses thereof |
| AR123603A1 (es) * | 2020-09-24 | 2022-12-21 | Rhythm Pharmaceuticals Inc | Métodos de tratamiento de los trastornos asociados a la vía del receptor de melanocortina |
| WO2024083843A1 (en) | 2022-10-18 | 2024-04-25 | Confo Therapeutics N.V. | Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders |
| IL320947A (en) * | 2022-11-18 | 2025-07-01 | Rhythm Pharmaceuticals Inc | Methods for treating obesity with an mc4r agonist |
| WO2024155828A1 (en) * | 2023-01-18 | 2024-07-25 | Loma Linda University Health | Uses of aminopyridines in the management of weight and satiety |
| CN117143183B (zh) * | 2023-08-25 | 2024-08-16 | 广州益养生物科技有限公司 | 一种三肽、三肽盐或衍生物及其应用 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US5226895A (en) | 1989-06-05 | 1993-07-13 | Eli Lilly And Company | Multiple dose injection pen |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| AU1860697A (en) | 1995-09-08 | 1997-07-28 | Visionary Medical Products Corporation | Pen-type injector drive mechanism |
| US5688251A (en) | 1995-09-19 | 1997-11-18 | Becton Dickinson And Company | Cartridge loading and priming mechanism for a pen injector |
| US20030144174A1 (en) | 1998-12-09 | 2003-07-31 | Miles B. Brennan | Methods for identifying compounds useful for the regulation of body weight and associated conditions |
| US6603058B1 (en) | 1998-12-09 | 2003-08-05 | Oklahoma Medical Research Foundation | Non-human animal model for obesity and uses thereof |
| US7319107B2 (en) | 2001-11-08 | 2008-01-15 | Johnson & Johnson Consumer Companies, Inc. | 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators |
| DE10251673A1 (de) | 2001-11-09 | 2003-07-10 | Hoffmann La Roche | Alström-Syndrom-Gen, Genvarianten, codiertes Protein und Verfahren zur Diagnose des Alström-Syndroms |
| EP1594986B1 (de) | 2003-02-19 | 2011-07-13 | Universität Duisburg-Essen | Verwendung einer genveränderung im humanen gnas-gen zur vorhersage von erkrankungsrisiken, krankheitsverläufen und zur vorhersage des ansprechens auf krankheitstherapien |
| GB0304822D0 (en) | 2003-03-03 | 2003-04-09 | Dca Internat Ltd | Improvements in and relating to a pen-type injector |
| PT2316456T (pt) | 2003-04-29 | 2017-09-05 | Orexigen Therapeutics Inc | Composições para afetar a perda de peso compreendendo naltrexona e bupropion |
| US7968548B2 (en) | 2003-05-01 | 2011-06-28 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine compounds with diamine groups |
| AU2004251616A1 (en) | 2003-06-19 | 2005-01-06 | Eli Lilly And Company | Melanocortin receptor 4(MC4) agonists and their uses |
| US7910101B2 (en) | 2004-10-25 | 2011-03-22 | Centocor, Inc. | Melanocortin receptor binding mimetibodies, compositions, methods and uses |
| US8349797B2 (en) | 2005-07-08 | 2013-01-08 | Ipsen Pharma S.A.S. | Ligands of melanocortin receptors |
| JP4734411B2 (ja) | 2005-07-08 | 2011-07-27 | イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ | メラノコルチン受容体リガンド |
| US8247530B2 (en) | 2005-11-08 | 2012-08-21 | Palatin Technologies, Inc. | N-alkylated cyclic peptide melanocortin agonists |
| US8114844B2 (en) | 2006-03-30 | 2012-02-14 | Palatin Technologies, Inc. | Linear and cyclic melanocortin receptor-specific peptidomimetics |
| JP2010516653A (ja) | 2007-01-18 | 2010-05-20 | ノボ・ノルデイスク・エー／エス | 肥満の治療に使用される新規ペプチド |
| US20100016237A1 (en) | 2007-01-18 | 2010-01-21 | Novo Nordisk A/S | Novel Peptides for Use in the Treatment of Obesity |
| EP2106407A2 (en) | 2007-01-18 | 2009-10-07 | Novo Nordisk A/S | Novel peptides for use in the treatment of obesity |
| JP2010517943A (ja) | 2007-01-18 | 2010-05-27 | ノボ・ノルデイスク・エー／エス | 肥満の治療に使用される新規ペプチド |
| EP1974729A1 (en) | 2007-03-28 | 2008-10-01 | Santhera Pharmaceuticals (Schweiz) AG | Substituted imidazopyridine derivates as melanocortin- 4 receptor antagonists |
| US8563000B2 (en) | 2007-05-25 | 2013-10-22 | Ipsen Pharma S.A.S. | Melanocortin receptor ligands modified with hydantoin |
| EP2019100A1 (en) | 2007-07-19 | 2009-01-28 | Santhera Pharmaceuticals (Schweiz) AG | Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators |
| CA2727317C (en) | 2008-06-09 | 2015-02-17 | Palatin Technologies, Inc. | Melanocortin receptor-specific peptides for treatment of sexual dysfunction |
| US20090305960A1 (en) | 2008-06-09 | 2009-12-10 | Palatin Technologies, Inc | Melanocortin Receptor-Specific Peptides for Treatment of Obesity / 669 |
| AU2009278838B2 (en) | 2008-08-06 | 2013-07-25 | Pfizer Limited | Diazepine and diazocane compounds as MC4 agonists |
| CA2731442A1 (en) | 2008-08-29 | 2010-03-04 | Transtech Pharma, Inc. | Substituted aminothiazole derivatives, pharmaceutical compositions, and methods of use |
| US9393369B2 (en) | 2008-09-15 | 2016-07-19 | Medimop Medical Projects Ltd. | Stabilized pen injector |
| EP2168965A1 (en) | 2008-09-25 | 2010-03-31 | Santhera Pharmaceuticals (Schweiz) AG | Substituted imidazopyridine, imidazopyrazine, imidazopyridazine and imidazopyrimidine derivatives as melanocortin-4 receptor antagonists |
| WO2010037081A1 (en) | 2008-09-29 | 2010-04-01 | Palatin Technologies, Inc. | Melanocortin receptor-specific spiro-piperidine compounds |
| FR2937868B1 (fr) | 2008-11-04 | 2010-11-05 | Galderma Res & Dev | Composes antagonistes des recepteurs de la melanocortine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique |
| FR2937973B1 (fr) | 2008-11-04 | 2010-11-05 | Galderma Res & Dev | Modulateurs des recepteurs de la melanocortine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique |
| UA99555C2 (en) | 2008-11-12 | 2012-08-27 | Элджи Лайф Саенсез Лтд. | Melanocortin receptor agonists |
| JP2012509862A (ja) | 2008-11-25 | 2012-04-26 | ノヴォ・ノルディスク・アー／エス | 肥満の治療のためのペプチド |
| WO2010065799A2 (en) | 2008-12-04 | 2010-06-10 | Palatin Technologies, Inc. | Amine substituted piperidine melanocortin receptor-specific compounds |
| WO2010065802A2 (en) | 2008-12-04 | 2010-06-10 | Palatin Technologies, Inc. | Substituted pyrrolidine or imidazolidine melanocortin receptor-specific compounds |
| WO2010065800A1 (en) | 2008-12-04 | 2010-06-10 | Palatin Technologies, Inc. | Hydrazine substituted piperidine melanocortin receptor-specific compounds |
| WO2010065801A1 (en) | 2008-12-04 | 2010-06-10 | Palatin Technologies, Inc. | Amine substituted piperazine melanocortin receptor-specific compounds |
| EP2210885A1 (en) | 2009-01-14 | 2010-07-28 | Santhera Pharmaceuticals (Schweiz) AG | Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators |
| WO2010096854A1 (en) | 2009-02-27 | 2010-09-02 | Mimetica Pty Ltd | Methods of modulating the activity of the mc3 and/or mc4 receptors and treatment of conditions related to these receptors |
| CA2761607C (en) * | 2009-06-08 | 2018-09-04 | Yi-Qun Shi | Melanocortin receptor-specific peptides |
| UY32690A (es) | 2009-06-08 | 2011-01-31 | Astrazeneca Ab | Péptidos específicos para receptores de melanocortina |
| WO2010144341A2 (en) | 2009-06-08 | 2010-12-16 | Palatin Technologies, Inc. | Lactam-bridged melanocortin receptor-specific peptides |
| IN2012DN01493A (enExample) | 2009-08-05 | 2015-06-05 | Ipsen Pharma Sas | |
| HUE031856T2 (en) | 2009-08-31 | 2017-08-28 | Tensive Controls Inc | Stabilized melanocortin ligands |
| EP2501225B1 (en) * | 2009-11-16 | 2017-11-01 | Ipsen Pharma S.A.S. | Pharmaceutical compositions of melanocortin receptor ligands |
| BR112012021231A2 (pt) | 2010-02-26 | 2015-09-08 | Basf Plant Science Co Gmbh | método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto |
| US20130012432A1 (en) | 2010-02-26 | 2013-01-10 | Novo Nordisk A/S | Peptides for Treatment of Obesity |
| LT3539551T (lt) * | 2011-12-29 | 2022-01-10 | Rhythm Pharmaceuticals, Inc. | Su melanokortino-4 receptoriumi susijusių sutrikimų gydymo būdas heterozigotiniuose nešiotojuose |
| US10196425B2 (en) * | 2013-03-15 | 2019-02-05 | Rhythm Pharmaceuticals, Inc. | Peptide compositions |
| EP2970389B1 (en) * | 2013-03-15 | 2020-08-19 | Rhythm Pharmaceuticals, Inc. | Pharmaceutical compositions |
| PT3356386T (pt) * | 2015-09-30 | 2024-05-17 | Rhythm Pharmaceuticals Inc | Método de tratamento de distúrbios associados à via do receptor da melanocortina-4 |
-
2016
- 2016-09-29 PT PT167821503T patent/PT3356386T/pt unknown
- 2016-09-29 PL PL16782150.3T patent/PL3356386T3/pl unknown
- 2016-09-29 JP JP2018517270A patent/JP6940853B2/ja active Active
- 2016-09-29 AU AU2016330772A patent/AU2016330772A1/en not_active Abandoned
- 2016-09-29 CA CA3000673A patent/CA3000673A1/en active Pending
- 2016-09-29 EP EP24150717.7A patent/EP4360704A3/en active Pending
- 2016-09-29 JP JP2018517274A patent/JP7051106B2/ja active Active
- 2016-09-29 FI FIEP16782150.3T patent/FI3356386T3/fi active
- 2016-09-29 IL IL299541A patent/IL299541A/en unknown
- 2016-09-29 WO PCT/US2016/054455 patent/WO2017059075A1/en not_active Ceased
- 2016-09-29 WO PCT/US2016/054457 patent/WO2017059076A1/en not_active Ceased
- 2016-09-29 AU AU2016330773A patent/AU2016330773A1/en not_active Abandoned
- 2016-09-29 CN CN201680064771.4A patent/CN108601816A/zh active Pending
- 2016-09-29 EP EP21204226.1A patent/EP4029513A1/en active Pending
- 2016-09-29 KR KR1020187012330A patent/KR20180063221A/ko active Pending
- 2016-09-29 US US15/764,730 patent/US20180215790A1/en active Pending
- 2016-09-29 CN CN201680057324.6A patent/CN108431023B/zh active Active
- 2016-09-29 MA MA043040A patent/MA43040A/fr unknown
- 2016-09-29 EP EP16782150.3A patent/EP3356386B1/en active Active
- 2016-09-29 EP EP16782343.4A patent/EP3355905A1/en not_active Withdrawn
- 2016-09-29 MA MA043038A patent/MA43038A/fr unknown
- 2016-09-29 US US15/764,725 patent/US10960046B2/en active Active
- 2016-09-29 CA CA3000670A patent/CA3000670A1/en active Pending
- 2016-09-29 BR BR112018006674-5A patent/BR112018006674A2/en active Search and Examination
- 2016-09-29 HK HK19101826.7A patent/HK1259424A1/zh unknown
- 2016-09-29 DK DK16782150.3T patent/DK3356386T3/da active
- 2016-09-29 SG SG10202101510XA patent/SG10202101510XA/en unknown
- 2016-09-29 ES ES16782150T patent/ES2985734T3/es active Active
- 2016-09-29 MX MX2018003983A patent/MX2018003983A/es unknown
-
2018
- 2018-03-27 IL IL258412A patent/IL258412B2/en unknown
- 2018-03-28 MX MX2023003358A patent/MX2023003358A/es unknown
- 2018-04-23 ZA ZA2018/02704A patent/ZA201802704B/en unknown
-
2021
- 2021-02-09 US US17/171,563 patent/US12263202B2/en active Active
- 2021-03-05 AU AU2021201448A patent/AU2021201448A1/en not_active Abandoned
- 2021-03-15 JP JP2021041611A patent/JP2021088611A/ja active Pending
- 2021-04-06 JP JP2021064764A patent/JP7752373B2/ja active Active
-
2022
- 2022-01-20 IL IL289996A patent/IL289996B2/en unknown
- 2022-04-04 US US17/712,752 patent/US20220226425A1/en active Pending
- 2022-09-28 JP JP2022155051A patent/JP2022173426A/ja active Pending
- 2022-11-29 AU AU2022279420A patent/AU2022279420B2/en active Active
-
2023
- 2023-03-20 JP JP2023044399A patent/JP2023078335A/ja active Pending
- 2023-09-12 AU AU2023229494A patent/AU2023229494A1/en active Pending
-
2024
- 2024-09-25 US US18/895,435 patent/US20250195606A1/en active Pending
- 2024-11-25 JP JP2024204921A patent/JP2025019234A/ja active Pending
- 2024-12-19 AU AU2024278597A patent/AU2024278597A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018531937A5 (enExample) | ||
| JP2021102650A5 (enExample) | ||
| Drucker | GLP-1 physiology informs the pharmacotherapy of obesity | |
| US20250195606A1 (en) | Method of treating melanocortin-4 receptor pathway-associated disorders | |
| Paran et al. | Octreotide treatment in patients with severe acute pancreatitis | |
| JP2006515351A5 (enExample) | ||
| US11702448B2 (en) | Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers | |
| Kim et al. | Two novel insulin receptor gene mutations in a patient with Rabson-Mendenhall syndrome: the first Korean case confirmed by biochemical, and molecular evidence | |
| Kim et al. | Potential of a novel long-acting glucagon analog, HM15136, for the treatment of obesity | |
| JPWO2022067086A5 (enExample) | ||
| JP7242059B2 (ja) | シェーグレン症候群の治療用ペプチド | |
| RU2022132255A (ru) | Способ лечения нарушений, ассоциированных с путем рецептора меланокортина 4 | |
| US6603058B1 (en) | Non-human animal model for obesity and uses thereof | |
| Tombal et al. | Optimal testosterone control and Eligard® | |
| Staykova et al. | Infusion of soluble myelin basic protein protects long term against induction of experimental autoimmune encephalomyelitis | |
| HK40077660A (en) | Melanocortin-4 receptor agonists for the treatment of disorders characterised by pomc gene hypermethylation | |
| RU2785889C1 (ru) | Способ лечения нарушений, ассоциированных с путем рецептора меланокортина 4 | |
| Juriaans et al. | Eight years of growth hormone treatment in a patient with Schaaf-Yang Syndrome | |
| Ata et al. | Effects of Ileal Interposition on Plasma Glucagon Like Peptide (GLP-1) and Pancreas GLP-1 Receptor Expression in Rats with Metabolic Syndrome | |
| Galashin | Treatment of inflammatory bowel disease with interleukin-10 | |
| Taylor et al. | # 135 Long-term neuro-endocrine-immune effects of traumatic brain injury | |
| Page | Analgesia administration attenuates surgery-induced tumor promotion | |
| WO2008081013A1 (en) | Use of somatostatin analogs in cluster headache | |
| Holzenberger | PL8 IGF-1 receptor in adults: What the cell-specific knockouts tell us | |
| Sachatello | The Effect of Pentobarbital on Exocrine Pancreatic Secretion with a Review of the Literature on the Effects of Barbiturates on Gastrointestinal Secretions in General |